- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06326047
En forskningsstudie som sammenligner hvor godt ulike doser av medisinen NN0519-0130 senker blodsukkeret hos personer med type 2-diabetes
Undersøkelse av sikkerheten og effekten av NNC0519-0130 én gang i uken hos deltakere med type 2-diabetes – en dosefinnende studie
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
New South Wales
-
Campbelltown, New South Wales, Australia, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australia, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australia, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australia, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australia, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australia, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australia, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australia, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australia, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Hospital
-
-
-
-
-
Québec, Canada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Canada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Canada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Canada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Canada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Canada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Canada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Canada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Canada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Canada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
California
-
Chula Vista, California, Forente stater, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Forente stater, 93720
- Valley Research
-
Inglewood, California, Forente stater, 90301
- 310 Clinical Research
-
La Mesa, California, Forente stater, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Forente stater, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Forente stater, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Forente stater, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Forente stater, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Forente stater, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Forente stater, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Forente stater, 91602
- Med Partners, Inc.
-
Torrance, California, Forente stater, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Forente stater, 92780
- University Clin Investigators
-
Walnut Creek, California, Forente stater, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Forente stater, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Forente stater, 33756
- Innovative Research of W FL
-
Miami, Florida, Forente stater, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Forente stater, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Forente stater, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Forente stater, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Forente stater, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Forente stater, 20745
- MD Medical Research
-
Rockville, Maryland, Forente stater, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Forente stater, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Forente stater, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Forente stater, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Forente stater, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Forente stater, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Forente stater, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Forente stater, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Forente stater, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Forente stater, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Forente stater, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Forente stater, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Forente stater, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Forente stater, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Forente stater, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Forente stater, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Forente stater, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Forente stater, 75230
- Zenos Clinical research
-
Forney, Texas, Forente stater, 75126
- Care United Research, LLC
-
Houston, Texas, Forente stater, 77004
- Endocrine Associates Houston
-
Houston, Texas, Forente stater, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Forente stater, 75039
- Tekton Research
-
Lewisville, Texas, Forente stater, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Forente stater, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Forente stater, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Forente stater, 23606
- TPMG Clinical Research
-
-
-
-
-
Bengaluru, India, 560054
- MS Ramaiah
-
New Delhi, India, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, India, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, India, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, India, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, India, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japan, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Seoul, Sør -Korea, 05505
- Asan Medical Center
-
Seoul, Sør -Korea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Sør -Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Sør -Korea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Sør -Korea, 13620
- Seoul National University Bundang Hospital
-
-
-
-
Free State
-
Bloemfontein, Free State, Sør-Afrika, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Sør-Afrika, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Sør-Afrika, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Sør-Afrika, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Sør-Afrika, 4170
- Dr T Padayachee
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentell: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentell: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentell: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Eksperimentell: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo komparator: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Aktiv komparator: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Tidsramme: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Tidsramme: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Tidsramme: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NN9541-4945
- U1111-1291-9196 (Annen identifikator: World Health Organization (WHO))
- jRCT2031230704 (Registeridentifikator: JRCT)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .